--- title: "Krystal Biotech Inc. Company Profile" description: "Research and investment analysis framework for Krystal Biotech Inc. SEC EDGAR lists its industry as Biological Products, (No Diagnostic Substances)." canonical: https://www.getswoopr.com/stocks/companies/krystal-biotech-inc/ source: "Swoopr Investment: https://www.getswoopr.com" --- # Krystal Biotech Inc. Company Profile ## Direct Answer **Krystal Biotech Inc. (KRYS)** is a U.S.-listed company in Swoopr's Dow Jones U.S. Total Stock Market research set. SEC EDGAR lists its industry as **Biological Products, (No Diagnostic Substances)**. This profile is a research framework: it does not state company-specific segments, products, management, financial figures or historical claims that have not been verified against primary sources. The research objective is to determine how Krystal Biotech Inc. converts pharmaceuticals, biotechnology, medical devices, diagnostics, care delivery or health-services infrastructure into durable per-share cash generation. The page therefore emphasizes revenue mechanics, customers, margins, capital intensity, cash conversion, competition, risks, scenario analysis and monitoring signals rather than a stock-price prediction. ## What Do the Latest SEC Filings Show for Krystal Biotech? These are figures Krystal Biotech reported in its own SEC filings, read from the SEC's XBRL data, so the page has a fixed starting point before any of the research questions below. They describe reported history and are not a forecast. | Item | As reported | | --- | --- | | Ticker symbol | KRYS | | SEC industry classification | 2836, Biological Products, (No Diagnostic Substances) | | Fiscal year ends | December 31 | | Latest fiscal year reported | FY2025, ended December 31, 2025 | | Revenue | $389 million | | Net income (loss) | $205 million | | Operating cash flow | $201 million | | Cash and cash equivalents | $496 million | Source: [SEC EDGAR: Krystal Biotech, Inc. Form 10-K filed February 17, 2026](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000016/krys-20251231.htm). ## Company Snapshot | Field | Value | | --- | --- | | Company | Krystal Biotech Inc. | | Primary ticker | KRYS | | Security lines mapped to issuer | KRYS | | SEC industry (SIC) | [Biological Products, (No Diagnostic Substances)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1711279) | | Index | Dow Jones U.S. Total Stock Market Index | | Listing data as of | 2026-08-31 | | Content status | Research framework; company-specific facts not yet verified against primary sources | Unverified fields such as current CEO, headquarters, employee count, CIK, fiscal year end, reported segments and current financial figures are intentionally omitted from this profile. ## What the Company Does Research on Krystal Biotech Inc. (KRYS) is most productive when the business model, cash-flow engine and risk structure are separated from market sentiment. SEC EDGAR lists the industry of Krystal Biotech Inc. as Biological Products, (No Diagnostic Substances). Within that boundary, the analytical starting point is the sector's typical economic chain: pharmaceuticals, biotechnology, medical devices, diagnostics, care delivery or health-services infrastructure. This matters because headline growth can look similar while the quality of that growth differs materially. A strong review should test product adoption, procedure or prescription volumes, and cash runway for pre-profit issuers together rather than treating any one figure as decisive. ## How the Company Makes Money Research on Krystal Biotech Inc. (KRYS) is most productive when the business model, cash-flow engine and risk structure are separated from market sentiment. For Krystal Biotech Inc., start by translating reported revenue into the operating causes behind it. In this sector those causes often include reimbursement, new indications, capacity and commercial execution, and product adoption. This matters because headline growth can look similar while the quality of that growth differs materially. The same discipline should be applied to pipeline milestones, procedure or prescription volumes when relevant, and operating margin, because a favorable top-line result can have very different implications depending on margin, capital intensity and cash conversion. ## Revenue Engine For Krystal Biotech Inc. (KRYS), the central analytical task is to connect reported financial results to the underlying drivers that can persist across cycles. The customer map for Krystal Biotech Inc. should be built from disclosed end markets rather than assumed from its sector label. Likely research categories to validate include government health programs and research organizations, patients, providers, and hospitals. The analytical question is why those customers choose the offering, how concentrated the relationship is, and whether purchasing behavior is recurring or transactional. This matters because headline growth can look similar while the quality of that growth differs materially. Evidence of switching costs, contractual duration, distribution reach or product criticality should be cited directly when present. - **Capacity And Commercial Execution**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Product Adoption**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Procedure Or Prescription Volumes**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. ## Business Segments and Reporting Map A useful way to analyze Krystal Biotech Inc. (KRYS) is to begin with the operating mechanism rather than the share price. The most useful risk work on Krystal Biotech Inc. links a risk to a measurable transmission mechanism. For this sector, relevant categories can include patent or exclusivity loss, reimbursement pressure, product safety, and customer concentration. A risk matters through the revenue, margin, cash-flow or balance-sheet path it could affect, so it is not listed merely because it appears in a filing. The distinction is important because accounting results can move before, or after, the operating drivers that ultimately determine cash returns. Monitoring should therefore connect each risk to a leading indicator or disclosure that can be checked over time. ## Products, Services and Commercial Offerings Research on Krystal Biotech Inc. (KRYS) is most productive when the business model, cash-flow engine and risk structure are separated from market sentiment. Supply-chain analysis for Krystal Biotech Inc. should identify where bargaining power sits from upstream inputs through end demand. A practical map begins with clinical development or engineering, moves through regulated manufacturing and provider and payer channels, and ends with scientific research and intellectual property. Company-specific suppliers or customers should only be named when supported by filings or other authoritative evidence. This matters because headline growth can look similar while the quality of that growth differs materially. Concentration, lead times, geographic dependence and substitution difficulty are more informative than a decorative list of counterparties. ## Customers and Demand Structure Investors studying Krystal Biotech Inc. (KRYS) should treat the company as an operating system of customers, assets, costs, capital and competitive choices, not merely as a ticker. Macro sensitivity should be tested rather than assumed. Variables worth checking for Krystal Biotech Inc. include employment and insurance coverage, interest rates for development-stage issuers, demographics, and health-care utilization. The goal is to determine whether these variables affect unit demand, pricing, financing cost, working capital, asset utilization or customer solvency. This matters because headline growth can look similar while the quality of that growth differs materially. A robust dossier distinguishes direct exposure from second-order correlations and avoids implying that every macro variable is equally important. - **Pharmacies**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Government Health Programs And Research Organizations**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Patients**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. ## Geographic Exposure Research on Krystal Biotech Inc. (KRYS) is most productive when the business model, cash-flow engine and risk structure are separated from market sentiment. Capital allocation is where operating performance is converted into per-share outcomes. For Krystal Biotech Inc., follow where capital goes: internal investment, capital expenditures, acquisitions, divestitures, dividends, repurchases, debt changes and equity issuance. In a business like this, research and development spending and pipeline milestones can be especially informative when interpreted alongside returns on incremental capital. The distinction is important because accounting results can move before, or after, the operating drivers that ultimately determine cash returns. The right question is not whether management spent more or less, but whether each use of capital improved durable cash-generation capacity per share. ## Business Model Research on Krystal Biotech Inc. (KRYS) is most productive when the business model, cash-flow engine and risk structure are separated from market sentiment. The financial statements of Krystal Biotech Inc. should be read as one connected system. Income-statement growth means more when it is read against balance-sheet investment and cash-flow conversion: compare changes in procedure or prescription volumes when relevant with operating margin, free cash flow, and product concentration. Health-care economics are unusually dependent on evidence, regulation and reimbursement. Reported growth must be connected to product durability, exclusivity, clinical value, payer acceptance, manufacturing reliability and the cost of sustaining the next generation of products. This matters because headline growth can look similar while the quality of that growth differs materially. Persistent divergence between earnings and cash generation deserves an explanation grounded in working capital, capital expenditures, non-cash compensation, acquisitions or other company-specific factors. For Krystal Biotech Inc., verify the actual revenue mechanisms, recurring, transactional, subscription, licensing, advertising, spread, fee, product, manufacturing, service or another model, and document only the mechanisms supported by current filings. Health-care economics are unusually dependent on evidence, regulation and reimbursement. Reported growth must be connected to product durability, exclusivity, clinical value, payer acceptance, manufacturing reliability and the cost of sustaining the next generation of products. ## Company Economics A useful way to analyze Krystal Biotech Inc. (KRYS) is to begin with the operating mechanism rather than the share price. SEC EDGAR lists the industry of Krystal Biotech Inc. as Biological Products, (No Diagnostic Substances). Within that boundary, the analytical starting point is the sector's typical economic chain: pharmaceuticals, biotechnology, medical devices, diagnostics, care delivery or health-services infrastructure. This matters because headline growth can look similar while the quality of that growth differs materially. A strong review should test procedure or prescription volumes, clinical and regulatory milestones, and gross margin together rather than treating any one figure as decisive. ## How to Read the Income Statement Investors studying Krystal Biotech Inc. (KRYS) should treat the company as an operating system of customers, assets, costs, capital and competitive choices, not merely as a ticker. For Krystal Biotech Inc., start by translating reported revenue into the operating causes behind it. In this sector those causes often include procedure or prescription volumes, clinical and regulatory milestones, reimbursement, and new indications. That framework helps separate durable improvement from temporary benefits created by pricing, mix, working capital or a favorable cycle. The same discipline should be applied to cash runway for pre-profit issuers, product concentration, and return on invested capital, because a favorable top-line result can have very different implications depending on margin, capital intensity and cash conversion. ## How to Read the Balance Sheet A useful way to analyze Krystal Biotech Inc. (KRYS) is to begin with the operating mechanism rather than the share price. The customer map for Krystal Biotech Inc. should be built from disclosed end markets rather than assumed from its sector label. Likely research categories to validate include providers, hospitals, payers, and pharmacies. The analytical question is why those customers choose the offering, how concentrated the relationship is, and whether purchasing behavior is recurring or transactional. The distinction is important because accounting results can move before, or after, the operating drivers that ultimately determine cash returns. Evidence of switching costs, contractual duration, distribution reach or product criticality should be cited directly when present. ## How to Read Cash Flow Investors studying Krystal Biotech Inc. (KRYS) should treat the company as an operating system of customers, assets, costs, capital and competitive choices, not merely as a ticker. The most useful risk work on Krystal Biotech Inc. links a risk to a measurable transmission mechanism. For this sector, relevant categories can include regulatory delay, patent or exclusivity loss, reimbursement pressure, and product safety. A risk matters through the revenue, margin, cash-flow or balance-sheet path it could affect, so it is not listed merely because it appears in a filing. This matters because headline growth can look similar while the quality of that growth differs materially. Monitoring should therefore connect each risk to a leading indicator or disclosure that can be checked over time. ## Metrics That Matter Most Investors studying Krystal Biotech Inc. (KRYS) should treat the company as an operating system of customers, assets, costs, capital and competitive choices, not merely as a ticker. Supply-chain analysis for Krystal Biotech Inc. should identify where bargaining power sits from upstream inputs through end demand. A practical map begins with regulated manufacturing, moves through provider and payer channels and patients and care settings, and ends with clinical development or engineering. Company-specific suppliers or customers should only be named when supported by filings or other authoritative evidence. A disciplined review therefore asks what changed operationally, how much capital was required, and whether the change can repeat. Concentration, lead times, geographic dependence and substitution difficulty are more informative than a decorative list of counterparties. - **Cash Runway For Pre-Profit Issuers**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Product Concentration**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Return On Invested Capital**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. ## Competitive Position A useful way to analyze Krystal Biotech Inc. (KRYS) is to begin with the operating mechanism rather than the share price. Macro sensitivity should be tested rather than assumed. Variables worth checking for Krystal Biotech Inc. include interest rates for development-stage issuers, demographics, health-care utilization, and government reimbursement policy. The goal is to determine whether these variables affect unit demand, pricing, financing cost, working capital, asset utilization or customer solvency. This matters because headline growth can look similar while the quality of that growth differs materially. A robust dossier distinguishes direct exposure from second-order correlations and avoids implying that every macro variable is equally important. ## Industry Position For Krystal Biotech Inc. (KRYS), the central analytical task is to connect reported financial results to the underlying drivers that can persist across cycles. Capital allocation is where operating performance is converted into per-share outcomes. For Krystal Biotech Inc., follow where capital goes: internal investment, capital expenditures, acquisitions, divestitures, dividends, repurchases, debt changes and equity issuance. In a business like this, product concentration and return on invested capital can be especially informative when interpreted alongside returns on incremental capital. That framework helps separate durable improvement from temporary benefits created by pricing, mix, working capital or a favorable cycle. The right question is not whether management spent more or less, but whether each use of capital improved durable cash-generation capacity per share. ## Supply Chain and Dependencies The investment case for Krystal Biotech Inc. (KRYS) becomes clearer when revenue drivers, cost behavior, balance-sheet demands and competitive constraints are examined together. The financial statements of Krystal Biotech Inc. should be read as one connected system. Income-statement growth means more when it is read against balance-sheet investment and cash-flow conversion: compare changes in gross margin with research and development spending, pipeline milestones, and operating margin. Health-care economics are unusually dependent on evidence, regulation and reimbursement. Reported growth must be connected to product durability, exclusivity, clinical value, payer acceptance, manufacturing reliability and the cost of sustaining the next generation of products. The distinction is important because accounting results can move before, or after, the operating drivers that ultimately determine cash returns. Persistent divergence between earnings and cash generation deserves an explanation grounded in working capital, capital expenditures, non-cash compensation, acquisitions or other company-specific factors. - **Scientific Research And Intellectual Property**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Clinical Development Or Engineering**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Regulated Manufacturing**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. ## Economic Sensitivity A useful way to analyze Krystal Biotech Inc. (KRYS) is to begin with the operating mechanism rather than the share price. SEC EDGAR lists the industry of Krystal Biotech Inc. as Biological Products, (No Diagnostic Substances). Within that boundary, the analytical starting point is the sector's typical economic chain: pharmaceuticals, biotechnology, medical devices, diagnostics, care delivery or health-services infrastructure. A disciplined review therefore asks what changed operationally, how much capital was required, and whether the change can repeat. A strong review should test new indications, capacity and commercial execution, and return on invested capital together rather than treating any one figure as decisive. - **Health-Care Utilization**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Government Reimbursement Policy**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Employment And Insurance Coverage**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. ## Capital Allocation For Krystal Biotech Inc. (KRYS), the central analytical task is to connect reported financial results to the underlying drivers that can persist across cycles. The customer map for Krystal Biotech Inc. should be built from disclosed end markets rather than assumed from its sector label. Likely research categories to validate include providers, hospitals, payers, and pharmacies. The analytical question is why those customers choose the offering, how concentrated the relationship is, and whether purchasing behavior is recurring or transactional. The distinction is important because accounting results can move before, or after, the operating drivers that ultimately determine cash returns. Evidence of switching costs, contractual duration, distribution reach or product criticality should be cited directly when present. For Krystal Biotech Inc., reconcile internal investment, acquisitions, divestitures, dividends, repurchases, debt changes and equity issuance. The useful question is whether each use of capital increases durable cash-generation capacity per share after considering risk and the opportunity cost of capital. ## Growth Drivers Research on Krystal Biotech Inc. (KRYS) is most productive when the business model, cash-flow engine and risk structure are separated from market sentiment. The most useful risk work on Krystal Biotech Inc. links a risk to a measurable transmission mechanism. For this sector, relevant categories can include customer concentration, litigation, manufacturing quality, and clinical failure. A risk matters through the revenue, margin, cash-flow or balance-sheet path it could affect, so it is not listed merely because it appears in a filing. The objective is not to forecast a stock price; it is to understand what evidence would strengthen or weaken the business case. Monitoring should therefore connect each risk to a leading indicator or disclosure that can be checked over time. - **Procedure Or Prescription Volumes**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Clinical And Regulatory Milestones**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Reimbursement**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. ## Risk Factors Research on Krystal Biotech Inc. (KRYS) is most productive when the business model, cash-flow engine and risk structure are separated from market sentiment. Supply-chain analysis for Krystal Biotech Inc. should identify where bargaining power sits from upstream inputs through end demand. A practical map begins with regulated manufacturing, moves through provider and payer channels and patients and care settings, and ends with clinical development or engineering. Company-specific suppliers or customers should only be named when supported by filings or other authoritative evidence. This matters because headline growth can look similar while the quality of that growth differs materially. Concentration, lead times, geographic dependence and substitution difficulty are more informative than a decorative list of counterparties. - **Litigation**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Manufacturing Quality**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Clinical Failure**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. ## Bull, Base and Bear Operating Framework The investment case for Krystal Biotech Inc. (KRYS) becomes clearer when revenue drivers, cost behavior, balance-sheet demands and competitive constraints are examined together. Macro sensitivity should be tested rather than assumed. Variables worth checking for Krystal Biotech Inc. include health-care utilization, government reimbursement policy, employment and insurance coverage, and interest rates for development-stage issuers. The goal is to determine whether these variables affect unit demand, pricing, financing cost, working capital, asset utilization or customer solvency. This matters because headline growth can look similar while the quality of that growth differs materially. A robust dossier distinguishes direct exposure from second-order correlations and avoids implying that every macro variable is equally important. A bull case for Krystal Biotech Inc. names the operating drivers that outperform, a base case describes normal execution, and a bear case identifies what deteriorates. Each case should use measurable business conditions rather than a target share price. ## What Could Prove an Investment Thesis Wrong? Investors studying Krystal Biotech Inc. (KRYS) should treat the company as an operating system of customers, assets, costs, capital and competitive choices, not merely as a ticker. Capital allocation is where operating performance is converted into per-share outcomes. For Krystal Biotech Inc., follow where capital goes: internal investment, capital expenditures, acquisitions, divestitures, dividends, repurchases, debt changes and equity issuance. In a business like this, organic revenue growth and gross margin can be especially informative when interpreted alongside returns on incremental capital. A disciplined review therefore asks what changed operationally, how much capital was required, and whether the change can repeat. The right question is not whether management spent more or less, but whether each use of capital improved durable cash-generation capacity per share. ## What Investors Commonly Misunderstand Investors studying Krystal Biotech Inc. (KRYS) should treat the company as an operating system of customers, assets, costs, capital and competitive choices, not merely as a ticker. The financial statements of Krystal Biotech Inc. should be read as one connected system. Income-statement growth means more when it is read against balance-sheet investment and cash-flow conversion: compare changes in cash runway for pre-profit issuers with product concentration, return on invested capital, and gross margin. Health-care economics are unusually dependent on evidence, regulation and reimbursement. Reported growth must be connected to product durability, exclusivity, clinical value, payer acceptance, manufacturing reliability and the cost of sustaining the next generation of products. The objective is not to forecast a stock price; it is to understand what evidence would strengthen or weaken the business case. Persistent divergence between earnings and cash generation deserves an explanation grounded in working capital, capital expenditures, non-cash compensation, acquisitions or other company-specific factors. Common analytical errors for Krystal Biotech Inc. can include treating sector averages as company facts, confusing revenue growth with cash-value creation, ignoring share issuance or acquisition effects, and assuming a favorable cycle is permanent. Replace these general cautions with issuer-specific misconceptions after primary-source enrichment. ## What to Monitor Research on Krystal Biotech Inc. (KRYS) is most productive when the business model, cash-flow engine and risk structure are separated from market sentiment. SEC EDGAR lists the industry of Krystal Biotech Inc. as Biological Products, (No Diagnostic Substances). Within that boundary, the analytical starting point is the sector's typical economic chain: pharmaceuticals, biotechnology, medical devices, diagnostics, care delivery or health-services infrastructure. A disciplined review therefore asks what changed operationally, how much capital was required, and whether the change can repeat. A strong review should test capacity and commercial execution, product adoption, and gross margin together rather than treating any one figure as decisive. - **Return On Invested Capital**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Organic Revenue Growth**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Gross Margin**, For Krystal Biotech Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. ## Key Takeaways Research on Krystal Biotech Inc. (KRYS) is most productive when the business model, cash-flow engine and risk structure are separated from market sentiment. The customer map for Krystal Biotech Inc. should be built from disclosed end markets rather than assumed from its sector label. Likely research categories to validate include payers, pharmacies, government health programs and research organizations, and patients. The analytical question is why those customers choose the offering, how concentrated the relationship is, and whether purchasing behavior is recurring or transactional. The objective is not to forecast a stock price; it is to understand what evidence would strengthen or weaken the business case. Evidence of switching costs, contractual duration, distribution reach or product criticality should be cited directly when present. ## Questions Investors Should Ask The investment case for Krystal Biotech Inc. (KRYS) becomes clearer when revenue drivers, cost behavior, balance-sheet demands and competitive constraints are examined together. For Krystal Biotech Inc., start by translating reported revenue into the operating causes behind it. In this sector those causes often include product adoption, procedure or prescription volumes, clinical and regulatory milestones, and reimbursement. A disciplined review therefore asks what changed operationally, how much capital was required, and whether the change can repeat. The same discipline should be applied to free cash flow, cash runway for pre-profit issuers, and product concentration, because a favorable top-line result can have very different implications depending on margin, capital intensity and cash conversion. 1. What two or three variables explain most changes in Krystal Biotech Inc.'s revenue? 2. Which costs at Krystal Biotech Inc. are fixed, variable, or investment for future growth? 3. What evidence shows that Krystal Biotech Inc. has, or lacks, pricing power? 4. Which customers or channels matter most, and is concentration changing? 5. How well do reported earnings at Krystal Biotech Inc. convert to cash? 6. How much reinvestment is required to sustain the competitive position? 7. Which KPI would give the earliest warning of deterioration? 8. How exposed is Krystal Biotech Inc. to health-care utilization and government reimbursement policy? 9. Is capital allocation improving per-share economics? 10. What evidence would invalidate a positive long-term thesis? ## FAQ Is Krystal Biotech Inc. in the Dow Jones U.S. Total Stock Market Index? Krystal Biotech Inc. (KRYS) is in the Dow Jones U.S. Total Stock Market Index company list Swoopr compiled from U.S. listing data as of 2026-08-31. S&P Dow Jones Indices publishes current official membership. What sector is Krystal Biotech Inc. in? SEC EDGAR lists the industry of Krystal Biotech Inc. as Biological Products, (No Diagnostic Substances). That is an SEC filing classification, not a GICS sector. How does Krystal Biotech Inc. make money? This profile does not yet describe an issuer-specific revenue model. The latest annual report on SEC EDGAR sets out revenue streams, pricing and reported segments; the framework on this page shows how to read them. What metrics matter for Krystal Biotech Inc.? Candidate sector metrics include organic revenue growth, gross margin, research and development spending, pipeline milestones, procedure or prescription volumes when relevant. Keep only KPIs that current disclosures and the economics of Krystal Biotech Inc. show are material. What are the principal risks for Krystal Biotech Inc.? Start by testing clinical failure, regulatory delay, patent or exclusivity loss, reimbursement pressure, then add issuer-specific risks from current filings and connect each risk to an observable monitoring signal. Does this page recommend buying or selling KRYS? No. The dossier is educational research infrastructure and does not provide personalized investment advice or a price target. ## References - [S&P Dow Jones Indices: Dow Jones U.S. Total Stock Market Index](https://www.spglobal.com/spdji/en/indices/equity/dow-jones-us-total-stock-market-index/). Index identity and methodology context. - [S&P Dow Jones Indices methodology materials](https://www.spglobal.com/spdji/en/). Eligibility and maintenance framework. - [SEC EDGAR](https://www.sec.gov/edgar/search/). The SEC's company search is where to confirm Krystal Biotech Inc.'s legal identity, filings, segments and risks, and to read its financial statements. ## More in This Section - [Krystal Biotech Inc. Business Model Research Guide](https://www.getswoopr.com/stocks/companies/krystal-biotech-inc/business-model/) - [Krystal Biotech Inc. Metrics Guide](https://www.getswoopr.com/stocks/companies/krystal-biotech-inc/financial-metrics/) - [Krystal Biotech Inc. Risk Monitoring](https://www.getswoopr.com/stocks/companies/krystal-biotech-inc/risks-monitoring/) - [Krystal Biotech NBI Biotech Research: Pipeline, Catalysts & NBI Membership](https://www.getswoopr.com/stocks/companies/krystal-biotech-inc/nbi-membership/) **[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)** Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).